CN106110424A - Female tire Rh blood group incompatibility immunoadsorption therapy instrument - Google Patents
Female tire Rh blood group incompatibility immunoadsorption therapy instrument Download PDFInfo
- Publication number
- CN106110424A CN106110424A CN201610540909.5A CN201610540909A CN106110424A CN 106110424 A CN106110424 A CN 106110424A CN 201610540909 A CN201610540909 A CN 201610540909A CN 106110424 A CN106110424 A CN 106110424A
- Authority
- CN
- China
- Prior art keywords
- blood
- adsorber
- plasma
- blood plasma
- blood group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
- A61M1/3689—Chemical treatment by biological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0429—Red blood cells; Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/12—Blood circulatory system
Abstract
nullThe present invention relates to female tire Rh blood group incompatibility immunoadsorption therapy instrument of medical domain，It is characterized in that substituting mankind's Rh positive O type erythrocyte with rhesus monkey erythrocytes，Washed Red Blood Cells are replaced with the PB lysate of the PH7.4 of 25 and 35mmol/L again after 4 DEG C and 37 DEG C of normal saline clean，Until upper strata is colourless，Completely harmful in dialysis erythrocyte hemoglobin，The preparation Rhesus Macacus ghost containing D antigen，Assemble, after detection antigenicity, the adsorber that high-biocompatibility material is made，Ghost is made to form the cell adsorbent of highly dense compression through high speed centrifugation repeatedly，Import and export at adsorber and be respectively provided with screen cloth，Constitute the defence line preventing cell debris from leaching，After blood plasma filters，Rh antibody is combined into fixing complex by ghost therein，Erythrocytolysis thing is then adsorbed the screen cloth detention of device，The blood plasma removing morbid substance feeds back after adsorber leaches，To treat Hemolysis by removing blood plasma Rh antibody.
Description
Technical field
The present invention relates to female tire Rh blood group incompatibility immunoadsorption therapy instrument of medical domain, be mainly used in female tire Rh blood group not
Close anti-FE antibody and the removing of erythrocytolysis product in pregnant woman blood plasma.
Background technology
Fetus inherits father and the gene element of each half of mother, and FE can carry the antigen from male parent,
The blood group showing as fetus is different from parent.After the erythrocyte of fetus enters the blood circulation of parent, the immunity of induction parent
System produces antibody, and antibody enters fetal circulation system through Placenta Hominis, in conjunction with FE, makes FE be broken
Bad, cause female tire blood group incompatibility hemolytic disease of fetus an d neonate.
Human erythrocyte's blood group has 26 kinds, the blood group such as including abo blood group, Rh blood group and MN, Lew, Kell and Fya, but
The blood group that can cause female tire blood group incompatibility Hemolysis is most common with Rh blood group and abo blood group.Rh is Rhesus Macacus (Rhesus
Macacus) two letters of foreign language title.1940, the scientist such as blue moral stainer was with the erythrocyte immune of Rhesus Macacus
When Cavia porcellus and rabbit, result produces the antibody (agglutinin) of anti-rhesus monkey erythrocytes in Cavia porcellus and rabbit anteserum, then with containing this
The serum planting antibody mixes with the erythrocyte of people, finds that there are about 85% white erythrocyte can be shown by this serum agglutination
There is on these white erythrocyte the antigen identical with Rhesus Macacus, therefore referred to as Rh positive blood group；Separately there are about 15% white people
Erythrocyte not by this serum agglutination, referred to as Rh negative blood group, this blood group system i.e. be referred to as Rh blood group.Rh blood group antigen are
By on No. 1 chromosome 3, closely linked allele is determined, have 6 kinds of antigens, i.e. C and c, D and d, E and e.Owing to D resists
Former being found the earliest, antigenicity is the strongest, thus the most every D antigen positive person to be referred to as Rh positive, be referred to as Rh the moon without D antigen person
Property.The antigenicity of Rh blood group antigen determines the order of severity of Hemolysis, and D antigen can cause serious Hemolysis, secondly resists for E
Former, it is C, c and e antigen again, the antigenicity of d antigen is the most weak, there is no anti-d antibody at present and finds.Big with other in Han nationality of China
Part is national, and people positive for Rh accounts for 99%, and people negative for Rh only accounts for about 1%, but in other ethnic groups, Rh is negative
People more, if Miao ethnic group is 12.3%, Tartar is 15.8%.
Although the incidence rate of ABO incompatibility is the highest, but fetus haemolysis incidence rate is the lowest, even if there is haemolysis, symptom is also
Relatively light, few generation bilirubin encephalopathy and edema, trimester of pregnancy is without special handling.Although and Rh blood group incompatibility is rare, but it causes mother
The severity extent ABO incompatibility to be overweighted of tire blood group incompatibility Hemolysis, so to the diagnosis of Rh blood group incompatibility and prevention extremely
Important.Rh blood group incompatibility produces the Rh antibody (the anti-D of IgG) of a large amount of anti-FEs due to parent, rear broken in entering fetus body
Bad substantial amounts of FE, makes fetus severe anemia, anoxia, heart failure, hepar damnification, hypoproteinemia, hydrosarca, breast
Water, ascites even Intrauterine Fetal Death.At non-neonate, there is the jaundice time early in Rh blood group incompatibility haemolysis relatively ABO incompatibility,
Early occur that after birth in 12 hours, majority occurred in 24 hours.Due to haemolysis produce a large amount of bilirubin can not in time from
Liver get rid of, make neonatal jaundice increase the weight of, substantial amounts of bilirubin penetrate into brain cell and cause bilirubin encephalopathy, often die from severe anemia,
Heart failure, bilirubin encephalopathy, mortality rate is the highest.
Although serious Hemolysis can be caused by destroying the erythrocyte of fetus after in Rh antibody entrance fetus body, but certain
A little anemia of pregnant woman also can carry out Rh (D) the positive red blood cell sensitization body of pre-anti-intrusion by injecting Rh antibody in advance, and then can prevent Rh
The generation of Hemolysis.Owing to current most countries has forbidden carrying out D antigen immune, the source of the anti-D of polyclone Ig with volunteer
The most extremely limited, and utilize the Epstein-Barr virus conversion human B lymphocyte secretion anti-D of Ig or Epstein-Barr virus to convert and combine cell fusion preparation
The anti-D of Ig, the anti-D of Ig of bone-marrow-derived lymphocyte strain or hybridoma cell strain secretion because using EBV conversion in vivo still suffer from much asking
Topic, as contained EBV has potential pathogenic；May be with the pathogen such as HIV and hepatitis virus；With hybridoma technology production
The anti-D of Ig is containing Mus source protein, easily cause allergic reaction or with the oncogene of Mus, so by directly injecting Ig in vivo
Anti-D prevents Rh Hemolysis to be just restricted.
Treatment to female tire blood group incompatibility Hemolysis mainly has pregnancy period plasmapheresis, fetal transfusion, termination the most clinically
Gestation and neonatal exchange transfusion are treated.Anti-D titer needs to consider intrauterine transfusion more than 32, and fetal transfusion includes that fetus intraperitoneal is defeated
Blood and the blood transfusion of fetus Ink vessel transfusing, be respectively provided with certain risk, and none be proved effectively；Hyperbilirubinemia of newborn person can use
The Drug therapy such as blue light illumination, immunoglobulin'intravenous, if desired Blood exchanging therapy, Blood exchanging therapy is still molten for treatment neonate
The main method of disorders of blood；During gestation, anti-D titer is more than 64, need to consider replacement therapy of blood plasma, pregnant woman blood plasma displacement be exactly
To filter hemocyte and the blood plasma of method separation anemia of pregnant woman in extracorporeal circulation path, remove blood plasma displacement liquid (the fresh ice with equivalent
Freeze blood plasma or 5% albumin) supplement feedback, each replacement amount 2000～3000ml, speed 20～30ml/min, treatment time 2
～4h, every 1～3d treat 1 time；Or take anemia of pregnant woman's whole blood about 400ml every time, remove its blood plasma about 300ml after low-temperature centrifugation, supplement
Amount homotype fresh plasma, the most defeated Autoerythrocyte (RBC).Plasmapheresis proportionally can reduce pathogenic with removed plasma volume
The titre (titer) of antibody, it is thus possible to extend fetus survival and growth and development time in parent, can postpone termination of pregnancy
Time, it is that the anemia of pregnant woman of female tire ABO, Rh or other blood group incompatibility prevents miscarriage the good selection in treatment in early days in clinic, has preferably
Curative effect, also without other untoward reaction.But plasmapheresis can only remove the partial antibody in blood, it is impossible to stop the continuation of antibody
Produce, the female tire blood group incompatibility Hemolysis occurred can not be reversed, need to carry out plasmapheresis incessantly just effectively, the suitableeest
The anemia of pregnant woman of fetus edema, or the homozygote person that spouse is pathogenic antigens was there is, particularly in gestation before 20～22 weeks for once
While removing part pathogenic antibody, the most together eliminate substantial amounts of blood plasma (multiple beneficial composition), although make with displacement liquid
Supplement, but cannot completely supply and be removed blood plasma and various beneficial thereof, and the displacement liquid measure substituted is big, expense is held high
Expensive, supplement allosome blood plasma and easily cause the various side effect such as infectious disease and infusion reaction, which limits generally carrying out of plasmapheresis.
So, only remove pathogenic antibody in the urgent need to one, do not remove blood plasma and multiple beneficial composition thereof, without using blood
Slurry displacement liquid cheap, safely, the treatment new method of female tire blood group incompatibility Hemolysis that has no side effect.
Summary of the invention
In order to solve to attack for a long time the treatment problem of the female tire blood group incompatibility Hemolysis being unable to, present inventors have proposed the present invention.
The invention aims to provide female tire Rh blood group incompatibility immunoadsorption therapy instrument；Another object is intended to provide immunity
The preparation of adsorbing therapy instrument and application process.
The object of the present invention is achieved like this: takes the fresh rhesus monkey erythrocytes of q.s, respectively at 4 DEG C and 37 DEG C
Under the conditions of with normal saline clean 4 times, to remove erythrocyte surface immune antibody that may be present or natural antibody, then with
0.04mol/L Na2HPO4With 0.04mol/L NaH2PO4The PB of the PH7.4 that osmotic concentration is 25 and 35mmol/L of preparation splits
Solve liquid and replace Washed Red Blood Cells, finally clean until supernatant is colourless with normal saline, with harmful in erythrocyte of dialysing
Hemoglobin, be centrifuged 10min through 4 DEG C of 2500r/min, gained cell precipitation is the ghost containing D antigen, the most carefully
After born of the same parents' form and antigenicity, the assembling setup of entrances and exits made of high-biocompatibility material can stop the circle of specific particle mesh screen
Cylindricality adsorber, followed by high speed centrifugation are allowed to be formed the cell adsorbent of highly dense compression, and adsorber top and the bottom are respectively provided with cell sieve
Net, footpath, top is 500 mesh, and footpath, the end is 50 mesh, and liquid outlet arranges the cell strainer of 200 mesh, constitutes and prevents cell debris entrance from following
The second defence line of ring, arranges relief area between liquid entrance and mesh screen so that the stablizing, when blood plasma flows through suction of extracorporeal circulation
During adnexa, Rh antibody is combined into fixing immune complex by ghost therein, destroyed bib and therewith
The macromole immune complex being combined into is adsorbed the screen cloth detention of device, removes the blood plasma of morbid substance after adsorber leaches
Feed back internal, remove blood plasma Rh antibody and erythrocytolysis product with this.
Rhesus monkey erythrocytes contains the Rh antigen that human erythrocyte is common, is the native antigen of Rh antibody, and Rh antibody is people
The virulence factor of class mother's tire Rh blood group incompatibility Hemolysis, the present invention is with rhesus monkey erythrocytes as raw material, with PB lysate dialysis system
Become removal to be harmful to the hemoglobin of human body but retain the antigenicity of absorption Rh antibody and do not adsorb the natural anti-of anti-A and anti-B
The ghost of body, is followed by high speed centrifugation and makes the cell adsorbent of highly dense compression and be fixed on spy with tight intercellular substance
The adsorber of system, is conducive to compression cell surface and filters being fully contacted of blood plasma, thus resisting Rh because adding ghost
The uniform contact face of body and increase the effect of absorption Rh antibody, and because being provided with the special absorption of multiple minimum gateways micropore
Device screen cloth, to bib and the barrier properties of macromole antigen antibody complex, defines Rh (D) positive Rhesus blood shadow
Cell absorption Rh antibody and the double purified barrier of adsorber mesh screen machinery detention erythrocytolysis product, flow through adsorber
Rh antibody in blood plasma or amniotic fluid and the adsorbed removing of the erythrocytolysis product of Hemolysis patient, the blood plasma after purification feeds back,
Achieve the ghost preparing treatment Rh blood group incompatibility so that rhesus monkey erythrocytes substitutes mankind's Rh positive red blood cell, be a kind of
Save mankind's blood source, only remove pathogenic antibody and erythrocytolysis thing, do not remove blood plasma and multiple beneficial composition thereof without
Plasmapheresis liquid cheap, safely, the treatment new method of female tire blood group incompatibility Hemolysis that has no side effect.
Detailed description of the invention
Fig. 1 is the application schematic diagram of the female tire Rh blood group incompatibility immunoadsorption therapy instrument proposed according to the present invention.
Fig. 2 is the internal structure schematic diagram of the plasma separator proposed according to the present invention.
Fig. 3 is the internal structure schematic diagram of the adsorber proposed according to the present invention
In Fig. 1, one end of arterial blood line pipe (1) is connected with arteries, and the other end is through heparin pump (2) and blood pump
(3) being connected with plasma separator (4), plasma separator (4) is through blood plasma pump (6) and circulation line (7) adsorber in parallel with 2
(8), adsorber (9) be connected, be connected with circulation line (10), venous line (5) the most successively, the other end of venous line (5)
It is connected with vein blood vessel.
In Fig. 2,1 is plasma separator, and 2 is plasma separator inner chamber, and 3 is the micropore on plasma separator inner chamber tube wall, 4
Being the hemocyte that can not pass through micropore (3), 5 is the little molecule blood plasma components that can pass through micropore (3), and 6 is plasma separator exocoel,
7 is blood plasma flow export, and 8 is switchable valve.
In Fig. 3,1 is adsorber, the Rh positive ghost that 2 are fixed in adsorber, and 3 is the Rh entering adsorber
Antibody, 4 is the antigenantibody complex that Rh antibody is formed by Rh positive blood shadow Cell binding, and 5 is RBC fragment.
Below in conjunction with Fig. 1, Fig. 2 and Fig. 3, the enforcement to female tire Rh blood group incompatibility immunoadsorption therapy instrument that the present invention proposes
Scheme is explained in detail.
One, the preparation of the positive ghost of Rh (D)
1, primary cell
Not by the anti-A of ABO blood group system and positive " O " the type rhesus monkey erythrocytes of the Rh (D) of anti-B serum agglutination.
2, main agents
30mmol/L PB buffer: solution A is 0.04mol/L Na2HPO4(Na2HPO4.12H2O 14.328g is dissolved in
In 1000ml deionized water, room temperature storage is standby)；Second liquid is 0.04mol/LNaH2PO4(NaH2PO4.2H2O 6.24g is dissolved in
In 1000ml deionized water, room temperature storage is standby).Take respectively solution A 81.0ml mix with second liquid 19.0ml 40mmol/L
PB, then adds deionized water dilution 0.75 times on the basis of 40mmol/L PB buffer and becomes 30mmol/L PB buffering
Liquid, is made into 25 and 35mmol/L in proportion with method.Anti-D standard substance and Rh (D) normal erythrocytes are purchased from the safe biotechnology of Guangzhou connection
Company limited.
3, preparation method
(1) the fresh Rh positive O type rhesus monkey erythrocytes of q.s is taken, respectively under conditions of 4 DEG C and 37 DEG C, with
The centrifugal speed of 1500r/min × 5min, cleans erythrocyte 4～5 times with isopyknic normal saline, to remove erythrocyte surface
May the abo blood group of attachment and Rh blood group and other immune antibody or natural antibody.
(2) with 0.04mol/L Na2HPO4With 0.04mol/L NaH2PO4The osmotic concentration of preparation is 25 and 35mmol/L
The PB lysate of PH7.4, under the centrifugal condition of 4 DEG C and 2500r/min × 10min, alternately and repeatedly Washed Red Blood Cells, pass through
The alternate of osmotic concentration, promotes hemoglobin to give and is removed outside erythrocyte.
(3) finally clean until supernatant is colourless with normal saline, with blood harmful in erythrocyte of dialysing completely
Lactoferrin, precipitation is the ghost containing D antigen.
(4) detection of antigenicity: 1. ghost and anti-D standard substance 37 DEG C are hatched 5min, centrifuging and taking supernatant detects
Anti-D standard substance titer reduces numerical value and determines the antigenicity of ghost.Concrete grammar is: take 10, test tube, numbering 1 respectively
～10, the 1st pipe adds ghost precipitation 1.0ml, and other each pipes add normal saline 0.5ml, then inhale ghost from the 1st pipe
Precipitation 0.5ml joins the 2nd pipe, inhales 0.5ml to the 3rd pipe after mixing, is diluted to the 10th pipe, finally pipe sucking-off with same operation
0.5ml discards, and often pipe adds anti-D standard substance 0.5ml, hatches 5min for 37 DEG C, centrifugal after mix gently, so that complete coagulation, several to occur
Maximum dilution multiple without free cell represents the antigenicity of ghost, and extension rate is the biggest, and antigenicity is the strongest, adsorbs Rh
The ability of antibody is the strongest.Supernatant antibody titer can also be measured with Rh (D) normal erythrocytes and determine the antigen of ghost
Property；2. measuring supernatant antibody titer with Rh (D) normal erythrocytes, anti-D standard substance titer (known) deducts supernatant antibody effect
Valency is the antigenicity (titer) of ghost.Supernatant antibody titer detection method is: take 10 test tubes, respectively numbering 1～
10, each pipe adds normal saline 1ml, takes removal 1ml after supernatant 1ml joins the 1st pipe mixing and goes to the 2nd pipe, with same behaviour
Being diluted to the 10th pipe, finally pipe sucking-off 1ml liquid discards, serum 40 μ l Yu Rh (D) the normal erythrocytes 10 μ l that will have diluted
Mixing, hatches 10 minutes, centrifugal 5 minutes sentence read result, and the coagulation pipe of maximum dilution multiple is antigenicity (titer), and titer should
At more than 1:1500.
(5) content of hemoglobin detection method: with conventional hypotonic destruction ghost, so that conventional chemical is luminous or fluorescence divides
Analyse legal and in detection by quantitative ghost content of hemoglobin.
(6) ghost form: examine under a microscope form and the integrity of ghost, should be in circle shadow, no-reflection.
(7) for cellular morphology in circle shadow, no-reflection, high sensitivity routine hemoglobin qualitative detection is negative, quantitatively
Detection, less than the reference value lower bound of human normal plasma, the ghost of absorption Rh antibody titer more than 1: 1500, is left and taken standby.
Two, the preparation of adsorber
1, preparation principle
The present invention is because the free Rh antibody in pregnant woman blood plasma enters fetal blood based on female tire Rh blood group incompatibility Hemolysis
Caused by destruction FE, and Rh antibody can be combined absorption, and absorption by corresponding native antigen i.e. Rh positive red blood cell
The shell of device can be made into the mechanism preparation that the screen cloth only allowing specific little molecule to pass through passes through to stop relatively macromole.
2, material is prepared
Select the high-biocompatibility material close with Human vascular endothelial, it is desirable to good biocompatibility, without complement activation,
NIP reacts, without leukocyte, platelet, blood oxygen pressure, the change of complement C 3 C5a.Require by covalency, be grafted, polymerization etc.
Method improves the uniformity of material surface, hydrophilic, minimizing to blood coagulation and the impact of oxidative stress.Parent is added at adsorber inner surface
Hydrogel, as solidified 2 methylacryoyloxyethyl phosphocholines-butyl methacrylate in cellulose acetate membrane, by controlling
Wet-spinning procedure and generate CA/PMB30, CA/PMB80 and CA/PMB30-80, biocompatibility can be improved.By some anticoagulant
Matter is solidificated in carrier or adsorber inner surface, and blood coagulation, reduction heparin consumption can be suppressed even to realize no-rod tractor, as by liver
Element is aggregated on polyacrylonitrile-polymine film, can reduce the anaphylaxis of allergic constitution；Heparin covalent is attached to polyethers
Sulfone surface, can keep the mechanical property of polyether sulfone and improve the anticoagulation function of adsorber inner surface.On cellulose acetate film altogether
Valency solidification linoleic acid film, maybe will be covalently bound to polyacrylic linoleic acid and be grafted onto polysulfone membrane surface, can have preferably
Histocompatibility and anticoagulant effect.
3, the specification of adsorber enclosure
Make the hydrostatic column that footpath, the end is little, footpath, top is big of 50mm × 60mm, or make square, infundibulate, volume about 200
～300ml, top and the bottom are equipped with cell screen cloth, and footpath, top sieve number is 500 mesh, and footpath, end sieve number is 50 mesh, liquid outlet
Place arranges the cell strainer that mesh number is 200 mesh, constitutes the second defence line preventing cell debris from entering circulation, liquid entrance
And it is provided with relief area, the beneficially stability of system circulation between mesh screen.
4, the filling of adsorbent
Take Rh (D) positive Rhesus ghost prepared by the present invention, load adsorber, with 10000r/min be centrifuged 15～
30min, removes supernatant, reinstalls ghost, is centrifuged 15～30min with 10000r/min, repeats aforesaid operations, until inhaling
Adnexa is filled tight Rhesus Macacus ghost, capping, standby.
Three, the preparation of plasma separator
1, preparation principle: prepare according to the molecular size of hemocyte and blood plasma components.Such as visible component (blood in blood of human body
Cell) size be: normocyte is about 7 microns (μm), is the discoid cell of concave-concave；Leukocyte is divided into 5 kinds, neutral
Granulocyte about 12 μm, eosinophilic granulocyte is more bigger, and basophilic granulocyte is close with neutrophilic granulocyte, small lymphocyte 6-8 μm,
Approximating with erythrocyte, mononuclear cell is maximum, about 15-20 μm.Platelet is disc, and diameter 1～4 microns are to 7～8 microns not
Deng, the platelet mean diameter of people is 2-4 micron, thick 0.5～1.5 micron.
2 prepare material: can be selected for poly-vinegar non-woven fabrics, acetate fiber, absorbent cotton etc., it is desirable to good biocompatibility, hardly
Activating complement, do not cause inflammatory reaction, do not cause the change of leukocyte, platelet, blood oxygen pressure, complement C 3, C5a.Can pass through
Covalency, be grafted, the method such as polymerization improves the structure of material, the regulation microinhomogeneities on surface, hydrophilic, minimizing to blood coagulation and
The impact of oxidative stress thus improve sieving adequacy and biocompatibility, the generation of minimizing complication.
3 specifications: plasma separator stable in properties involved in the present invention, good biocompatibility, high score that permeability is high
Sub-polymer makes hollow fibre type filter, hollow-fiber film a diameter of 270～370 μm, and film thickness is 50 μm, and aperture is 0.2
～0.6 μm, fibre length is 13.5～26 μm.This hole is only permitted blood plasma and is filtered, but can stop all of cell component.
Four, the application of the present invention
Extracorporeal circulation branch road need to be collectively constituted with associated components.
1, the component of extracorporeal circulation branch road and purposes
(1) adsorber: internal Rh (D) positive Rhesus ghost is used for removing Rh antibody；Adsorber enclosure passes in and out
The mesh screen of mouth has the effect filtering the macromolecular complex that RBC fragment, Rh antibody and RBC fragment are formed.
(2) plasma separator: for washed corpuscles and blood plasma.
(3) sound pulse pressure monitoring: arterial blood pressure monitoring mainly in order to the stopping state of dynamic monitoring adsorber micropore, is additionally used
With monitoring extracorporeal circulation thrombosis, solidification and the change of pressure.When blood flow deficiency, arterial pressure will reduce；When having blood coagulation, thrombosis
Being formed, particularly during adsorber blockage of the micro orifice, arterial pressure will raise；Venous pressure monitoring is used for monitoring the pressure of pipeline blood backflow
Power, when adsorber blockage of the micro orifice, blood coagulation, thrombosis, blood flow deficiency and venous return syringe needle come off, venous pressure will
Declining, if the distortion blocking of bloody path return duct or backflow syringe needle occur blocking, venous pressure will raise.
(4) air monitering (Air Detector): be used for monitoring the air bubble of blood pathway, typically use ultrasonic listening
Principle, in order to avoid patient occurs air embolism to arrange.When having monitored air bubble, detecting system can drive dynamic,
Vein bloody path folder carrys out blocking blood flow, prevents the generation of danger.
(5) blood pump (Blood Pump): be used for promoting blood circulation being smoothed out with maintaining treatment, usual blood pump part
Often having rotary test speed function, to monitor the blood circumstance of patient, therefore blood pump runner sets with flute pitch and wants accurately, and
Need often to adjust, according to the situation of bloody path pump line, typically spacing is set as 3.2～3.3mm, can not be the most loose, otherwise can make
Blood flow detection is become to be forbidden；Also can not be too tight, otherwise can cause pipe breakage.
(6) heparin pump (Heparin Pump): heparin pump is equivalent to the micro-injection pump applied clinically, in order to continue to
Injecting heparin in sieving pipeline (patient blood), owing to the blood of patient circulates and air contact in vitro, is susceptible to blood coagulation
Phenomenon, uses heparin pump to be possible to prevent the generation of blood coagulation.
Additionally include temperature control system, liquid mixing system, off gas system, monitored conductivity system, ultrafiltration monitoring and leakage
The parts such as blood monitoring.In a word, on the basis of key constitution system of the present invention, be expected to be further development of automatization, hommization,
Personalization, modularity, automatically monitoring and regulation and control, liquid crystal display, judge the micro computer process such as alarm reason and ring off signal voluntarily
System.
2, the using method of the present invention
(1) install: with sterile working's connecting components, each portion such as including plasma separator, adsorber and each circulation line.
(2) aerofluxus: with physiological saline solution topping up separator, adsorber and each circulation line, gets rid of separator, adsorber
And gas in circulating line, bubble, go through, confirm without use after gas, bubble.
(3) logical liquid: arterial blood line pipe 1 is connected the arteries of HIV sufferers, the most again row of going through
Gas is the most complete, and liquid stream is the most unobstructed, and avoids managing the pollution of interior flow liquid.
(4) anticoagulant: inject anticoagulant (heparin) from heparin pump to liquid stream, be 2500 ∪ or 20～30 ∪/kg for the first time.
(5) start: arterial blood line pipe (1) is connected the arteries of therapist, venous line (5) is connected therapist
Vein blood vessel, then opens blood pump, and blood flow is 100～150ml/min, such as Fig. 1, when arterial blood is through arterial blood line pipe
(1) entering plasma separator (4), the blood plasma separated arrives adsorber through circulation line (7) under the effect of blood plasma pump (6)
(8), blood plasma to be full of, about 10 minutes, begin paying out blood plasma, flow out through circulation line (10), synchronize to irrigate blood to adsorber (9)
Slurry, when the blood plasma in adsorber (8) has nearly flowed, starts again at perfusion blood plasma, and now adsorber (9) begins paying out blood plasma,
Two adsorbers in parallel (8), adsorbers (9) are alternately.Such as Fig. 2, when blood to be separated enters plasma separator (1)
During inner chamber (2), through the effect of valve (8), little molecule blood plasma and the composition (5) thereof that can pass through micropore (3) enter outside separator
Chamber (6), then flows out through plasma outlet port (7), and the hemocyte (4) that can not pass through micropore (3) flows out through valve (8).Such as Fig. 3,
When Rh antibody (3) enters adsorber (1) with blood plasma, Rh positive Rhesus ghost (2) in adsorbed device is combined into anti-
Original antibody immune complex (4) and no longer move down, destroyed bib (5) and macromole in combination
Mesh screen that antigen antibody complex can not be exported by adsorber and by detention, the blood plasma after purification is isolated with plasma separator
The hemocyte come feeds back after converging, and so until the plasma circulation amount (usually 9L) being previously set, treatment just ends, as
The most supporting computer program controls, and whole therapeutic process is by computer control, and can detect duty at any time, and using can be more square
Just, automatization and safety.
Five, the checking of practical application of the present invention
In order to verify therapeutic efficiency, the present invention devises the simple method for testing bacterial resistance of adsorber effect: take prepared Henghe
Monkey ghost, joins and is incubated after 100 DEG C dissolve in 37 DEG C of 1.0% standby agarose C1-4B, be configured to 95% blood
The adsorbent of shadow cell concentration；Take 2.5 × 300mm Westergren's blood sedimentation tube 9 of sterilizing, draw the absorption of 95% ghost concentration
Agent, to 200mm scale, becomes semi-solid after adsorbent cooling；Buy blood station, center, Zhejiang Province fresh frozen plasma 200mL, separately purchase
Buy Rh antibody (people's anti-D type serum dry powder standard substance, Guangzhou Lian Tai Bioisystech Co., Ltd), be made into 1: 200 with fresh plasma,
1: 300,1: 600 antibody titer, routinely Rh (anti-D) titre detection method (with reference to description), detection confirms above-mentioned further
Whether the antibody titer prepared is consistent, and is referred to as (Rh) antibody (titre) before filter, and before respectively taking 10ml filter, antibody is injected separately into 3
Prop up the upper end blank pipe of blood sedimentation tube, after flowing through the adsorbent containing ghost of blood sedimentation tube lower floor, collect effluent, be referred to as filter
(Rh) antibody afterwards, Rh (anti-D) titre detection method confirms titre routinely, more respectively will after filter antibody through containing ghost
Making in cleanser to leach for the 2nd time, be so repeated 3 times filtration and antibody titer detection, result (table 1) illustrates, Rh antibody filters letter
Easily after adsorbent, major part Rh antibody is contained the adsorbent of ghost, accordingly through the 1st time, the 2nd time, the 3rd time
After filtration, the average titer of Rh antibody respectively from filter before 1: 367 reduce to filter after 1: 183,1: 58,1: 29, illustrate along with filter
Crossing the increase of number of times, Rh antibody constantly by ghost adsorption removal, thus can reduce anemia of pregnant woman's (neonate) blood plasma Rh
Antibody titer and treat the purpose of female tire blood group incompatibility Hemolysis.
Table 1 Rh antibody filters titre testing result (1/x) before and after the cleanser containing Rhesus Macacus ghost
Claims (10)
1. the female tire Rh blood group incompatibility immunoadsorption therapy instrument for medical domain, it is characterised in that prepare two kinds high and
The PB lysate of hyposmosis concentration, alternately washs rhesus monkey erythrocytes, makes the ghost removing hemoglobin, fills in out
The column adsorber of screen cloth is set at Kou, forms the cell adsorbent of highly dense compression with high speed centrifugation, constitute Rhesus Macacus blood shadow thin
Born of the same parents adsorb Rh antibody and the purification barrier of adsorber screen cloth detention erythrocytolysis thing, for the treatment of Hemolysis.
Female tire Rh blood group incompatibility immunoadsorption therapy instrument the most according to claim 1, it is characterised in that described height is with hypotonic
Saturating concentration refers to the PB lysate of the PH7.4 of 25mmol/L and 35mmol/L.
Female tire Rh blood group incompatibility immunoadsorption therapy instrument the most according to claim 2, it is characterised in that contain with 81.0ml
0.04mol/L Na2HPO4Solution A and 19.0ml NaH Han 0.04mol/L2PO4Second liquid be made into after 40mmol/L with deionization
Water is diluted to the PB lysate of the PH7.4 of 25 and 35mmol/L.
Female tire Rh blood group incompatibility immunoadsorption therapy instrument the most according to claim 1, it is characterised in that saturating at PB lysate
Analysis hemoglobin front and rear all cleans rhesus monkey erythrocytes with normal saline.
Female tire Rh blood group incompatibility immunoadsorption therapy instrument the most according to claim 4, it is characterised in that described normal saline
Clean rhesus monkey erythrocytes to refer to 4 DEG C and 37 DEG C each washings 2 times.
Female tire Rh blood group incompatibility immunoadsorption therapy instrument the most according to claim 1, it is characterised in that the shell of adsorber
Volume is 200～300ml, and top and the bottom are equipped with cell screen cloth, and footpath, top sieve number is 500 mesh, and footpath, end sieve number is 50 mesh,
Liquid outlet arranges the cell strainer that mesh number is 200 mesh, is provided with relief area between liquid entrance and mesh screen.
Female tire Rh blood group incompatibility immunoadsorption therapy instrument the most according to claim 1, it is characterised in that the hollow fibre of separator
Dimension filter membrane a diameter of 270～370 μm, film thickness is 50 μm, and aperture is 0.2～0.6 μm, and fibre length is 13.5～26 μm, energy
Filter blood plasma but all of cell component can not be filtered.
Female tire Rh blood group incompatibility immunoadsorption therapy instrument the most according to claim 1, it is characterised in that described high speed centrifugation
Refer to that 10000r/min is centrifuged 15～30min.
9. preparing extracorporeal circulation apparatus according to the arbitrary described female tire Rh blood group incompatibility immunoadsorption therapy instrument of claim 1-8
In application, it is characterised in that described extracorporeal circulation includes that one end of arterial blood line pipe (1) is through heparin pump (2) and blood pump (3)
Being connected with plasma separator (4), plasma separator (4) is through blood plasma pump (6) and circulation line (7) adsorber in parallel with two
(8), adsorber (9) be connected, be connected with circulation line (10), venous line (5) the most successively.
Application the most according to claim 9, it is characterised in that when enabling the extracorporeal circulation apparatus shown in Fig. 1, tremulous pulse
Blood through arterial blood line pipe (1) enter plasma separator (4), the blood plasma separated under the effect of blood plasma pump (6) through circulation
Pipeline (7) arrives adsorber (8), blood plasma to be full of, about 10 minutes, begins paying out blood plasma, flows out through circulation line (10), synchronization
Irrigate blood plasma to adsorber (9), when the blood plasma in adsorber (8) has nearly flowed, start again at perfusion blood plasma, now adsorber
(9) beginning paying out blood plasma, two adsorbers in parallel (8), adsorbers (9) are alternately.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610540909.5A CN106110424B (en) | 2016-07-01 | 2016-07-01 | Female tire Rh blood group incompatibility immunoadsorption therapy instrument |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610540909.5A CN106110424B (en) | 2016-07-01 | 2016-07-01 | Female tire Rh blood group incompatibility immunoadsorption therapy instrument |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106110424A true CN106110424A (en) | 2016-11-16 |
| CN106110424B CN106110424B (en) | 2019-01-22 |
Family
ID=57282705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610540909.5A Active CN106110424B (en) | 2016-07-01 | 2016-07-01 | Female tire Rh blood group incompatibility immunoadsorption therapy instrument |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106110424B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108732340A (en) * | 2018-06-04 | 2018-11-02 | 武汉纽康度生物科技股份有限公司 | A kind of chromatography buffer of removal red blood cell |
| CN109157695A (en) * | 2018-07-19 | 2019-01-08 | 翁炳焕 | Based on the female tire blood group incompatibility therapeutic device for removing pathogenic antibody |
| CN109157694A (en) * | 2018-07-01 | 2019-01-08 | 翁炳焕 | A kind of mother's tire blood group incompatibility immunoadsorption therapy instrument |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3975156A (en) * | 1975-11-10 | 1976-08-17 | Ortho Diagnostics, Inc. | Method and material for detecting and quantitating fetal erythrocytes in adults |
| CN101023101A (en) * | 2004-07-20 | 2007-08-22 | 西福根有限公司 | Anti-rhesus D recombinant polyclonal antibody and methods of manufacture |
| US20120214176A1 (en) * | 2011-02-22 | 2012-08-23 | Graham Henry A | Detection of specific antigens in a population of antigens |
| CN104718552A (en) * | 2012-09-13 | 2015-06-17 | 多伦多大学理事会 | System and method for fetal and maternal red blood cell counting |
-
2016
- 2016-07-01 CN CN201610540909.5A patent/CN106110424B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3975156A (en) * | 1975-11-10 | 1976-08-17 | Ortho Diagnostics, Inc. | Method and material for detecting and quantitating fetal erythrocytes in adults |
| CN101023101A (en) * | 2004-07-20 | 2007-08-22 | 西福根有限公司 | Anti-rhesus D recombinant polyclonal antibody and methods of manufacture |
| US20120214176A1 (en) * | 2011-02-22 | 2012-08-23 | Graham Henry A | Detection of specific antigens in a population of antigens |
| CN104718552A (en) * | 2012-09-13 | 2015-06-17 | 多伦多大学理事会 | System and method for fetal and maternal red blood cell counting |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108732340A (en) * | 2018-06-04 | 2018-11-02 | 武汉纽康度生物科技股份有限公司 | A kind of chromatography buffer of removal red blood cell |
| CN109157694A (en) * | 2018-07-01 | 2019-01-08 | 翁炳焕 | A kind of mother's tire blood group incompatibility immunoadsorption therapy instrument |
| CN109157695A (en) * | 2018-07-19 | 2019-01-08 | 翁炳焕 | Based on the female tire blood group incompatibility therapeutic device for removing pathogenic antibody |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106110424B (en) | 2019-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106110421B (en) | Rhesus monkey erythrocytes absorber | |
| CN106267422B (en) | Rh blood group incompatibility haemolysis disease therapeutic apparatus | |
| Kikugawa et al. | Filter columns for preparation of leukocyte-poor blood for transfusion | |
| CN106110424A (en) | Female tire Rh blood group incompatibility immunoadsorption therapy instrument | |
| CN106267407B (en) | Female tire Rh blood group incompatibility blood purifying therapeutical instrument | |
| Gurland et al. | Comparative evaluation of filters used in membrane plasmapheresis | |
| CN106267418B (en) | Female tire blood group incompatibility antibody adsorbing therapy instrument | |
| CN106110423B (en) | Female tire blood group incompatibility adsorbing therapy instrument | |
| Valbonesi et al. | Acute intravascular hemolysis in two patients transfused with dry-platelet units obtained from the same ABO incompatible donor | |
| CN106267423B (en) | People's Rh positive red blood cell absorber | |
| CN106139284A (en) | The film for the treatment of hemolytic event and device | |
| CN106267421B (en) | Female tire blood group incompatibility plasma purification device | |
| CN106344986B (en) | Female tire blood group incompatibility treats absorber | |
| CN106267405B (en) | Female tire blood group incompatibility haemolysis disease therapeutic apparatus | |
| CN109157694A (en) | A kind of mother's tire blood group incompatibility immunoadsorption therapy instrument | |
| CN109157692A (en) | People-people's cell merges the preparation of female tire blood group incompatibility treatment hybrid strain | |
| CN106178162B (en) | Treating AIDS organelle | |
| CN106166311B (en) | A kind of plasma purification system and its application | |
| CN109157695A (en) | Based on the female tire blood group incompatibility therapeutic device for removing pathogenic antibody | |
| CN109157690A (en) | Monkey-people's cell merges the preparation of female tire blood group incompatibility treatment hybrid strain | |
| CN109157691A (en) | The preparation of monkey-mouse cell fusion mother's tire blood group incompatibility treatment hybrid strain | |
| CN109157693A (en) | The preparation of people-mouse cell fusion mother's tire blood group incompatibility treatment hybrid strain | |
| CN113049508B (en) | Hemolytic test method for dialyzer hollow fiber | |
| Suaudeau et al. | The Ito “Flow‐Through” Centrifuge A New Device for Long‐Term (24 hours) Plasmapheresis without Platelet Deterioration | |
| CN106267420B (en) | HIV phagocyte device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200910 Address after: 310006 No. 1, bachelor Road, Zhejiang, Hangzhou Co-patentee after: Shu Lan (Hangzhou) Hospital Ltd. Patentee after: WOMEN'S HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG University Address before: The 317300 Ring Road Zhejiang County of Xianju province to the north, Xianju County Hospital Patentee before: Weng Binghuan |